Soleno Therapeutics (NASDAQ:SLNO) Rating Lowered to “Hold” at Lifesci Capital

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by Lifesci Capital from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company decreased their price target on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Zacks Research cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Wall Street Zen lowered Soleno Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Finally, Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research note on Tuesday, January 13th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $93.90.

Soleno Therapeutics Price Performance

Soleno Therapeutics stock opened at $52.35 on Monday. The business’s 50-day simple moving average is $38.17 and its 200 day simple moving average is $47.80. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of 227.62 and a beta of -2.81. Soleno Therapeutics has a 12-month low of $29.43 and a 12-month high of $90.32. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. As a group, research analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Institutional Investors Weigh In On Soleno Therapeutics

A number of hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Soleno Therapeutics by 1.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after purchasing an additional 189 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Soleno Therapeutics during the second quarter worth about $25,000. Avanza Fonder AB raised its position in shares of Soleno Therapeutics by 11.2% during the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock worth $148,000 after purchasing an additional 323 shares during the period. Principal Financial Group Inc. raised its position in shares of Soleno Therapeutics by 11.9% during the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock worth $216,000 after purchasing an additional 340 shares during the period. Finally, New York State Common Retirement Fund raised its position in shares of Soleno Therapeutics by 2.4% during the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock worth $1,055,000 after purchasing an additional 360 shares during the period. Institutional investors and hedge funds own 97.42% of the company’s stock.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for $53.00 per share in cash (about $2.9B), giving SLNO shareholders an immediate cash premium and a clear near‑term exit/liquidity event. Read More.
• Neutral Sentiment: Some research shops have set conservative near‑term views (reaffirmations / “peer perform” ratings) as the deal closes and integration risk becomes the focus; these are neutral for deal economics but can mute momentum. Read More.
• Negative Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT™ XR, citing the acquirer’s plan to sharpen focus on the U.S. market — this reduces near‑term international upside and could lower future revenue projections for the combined company. Read More.
• Negative Sentiment: Dozens of law firms have filed or are soliciting plaintiffs in securities class actions tied to Soleno’s 2025 DCCR/VYKAT XR trial/launch setbacks; litigation risk could create damages exposure, distraction and potential deal complications. Read More.
• Negative Sentiment: Multiple firms are investigating whether the $53/share deal is fair to public shareholders and several analysts have downgraded or cut targets — these actions can pressure the stock and may prompt negotiation or litigation over price. Read More.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.